Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis

Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270, 10.1038/s41586-020-2012-7 Fang, 2020, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir Med, 8, e21, 10.1016/S2213-2600(20)30116-8 Guan, 2020, Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, 382, 1708, 10.1056/NEJMoa2002032 Li, 2020, Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China, Clin Res Cardiol, 109, 531, 10.1007/s00392-020-01626-9 Zheng, 2020, COVID-19 and the cardiovascular system, Nat Rev Cardiol, 17, 259, 10.1038/s41569-020-0360-5 Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395, 1054 Yang, 2020, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, 8, 475, 10.1016/S2213-2600(20)30079-5 Lu, 2017, Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project), Lancet, 390, 2549, 10.1016/S0140-6736(17)32478-9 Nakamura, 2009, Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension, Int Heart J, 50, 501, 10.1536/ihj.50.501 Ferrario, 2005, Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation, 111, 2605, 10.1161/CIRCULATIONAHA.104.510461 Hoffmann, 2020, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, 10.1016/j.cell.2020.02.052 Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395, 565, 10.1016/S0140-6736(20)30251-8 Wan, 2020, Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus, J Virol, 94 Yan, 2020, Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2, Science, 367, 1444, 10.1126/science.abb2762 Gurwitz, 2020, Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics, Drug Dev Res, 81, 537, 10.1002/ddr.21656 Imai, 2005, Angiotensin-converting enzyme 2 protects from severe acute lung failure, Nature, 436, 112, 10.1038/nature03712 Kuba, 2005, A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat Med, 11, 875, 10.1038/nm1267 Zhang, 2020, Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target, Intensive Care Med, 46, 586, 10.1007/s00134-020-05985-9 HFSA/ACC/AHA, 2020, Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19, J Card Fail, 26, 370, 10.1016/j.cardfail.2020.04.013 Bean, 2020, Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust, Eur J Heart Fail, 22, 967, 10.1002/ejhf.1924 Conversano, 2020, Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia. A Case Series Study, Hypertension, 76, e10, 10.1161/HYPERTENSIONAHA.120.15312 Li, 2020, Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China, JAMA Cardiol, 5, 825, 10.1001/jamacardio.2020.1624 Mancia, 2020, Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19, N Engl J Med, 382, 2431, 10.1056/NEJMoa2006923 Mehta, 2020, Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19), JAMA Cardiol, 10.1001/jamacardio.2020.1855 Meng, 2020, Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension, Emerg Microbes Infect, 9, 757, 10.1080/22221751.2020.1746200 Reynolds, 2020, Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19, N Engl J Med, 382, 2441, 10.1056/NEJMoa2008975 Yang, 2020, Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study, Hypertension, 76, 51, 10.1161/HYPERTENSIONAHA.120.15143 Zhang, 2020, Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19, Circ Res, 126, 1671, 10.1161/CIRCRESAHA.120.317134 Zhou, 2020, Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors, Clin Exp Hypertens, 42, 656, 10.1080/10641963.2020.1764018 Nehme, 2019, An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology, J Cardiovasc Dev Dis, 6, 14, 10.3390/jcdd6020014 Santos, 2019, The renin-angiotensin system: going beyond the classical paradigms, Am J Physiol Heart Circ Physiol, 316, H958, 10.1152/ajpheart.00723.2018 Hollenberg, 1998, Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system, Hypertension, 32, 387, 10.1161/01.HYP.32.3.387 Belova, 2000, Angiotensin II-generating enzymes, Biochemistry (Mosc), 65, 1337, 10.1023/A:1002848402911 Dzau, 1989, Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses, J Hypertens, 7, 933, 10.1097/00004872-198912000-00001 Papademetriou, 2002, The potential role of AT(1)-receptor blockade in the prevention and reversal of atherosclerosis, J Hum Hypertens, 16, S34, 10.1038/sj.jhh.1001437 Matavelli, 2015, AT2 receptor activities and pathophysiological implications, J Cardiovasc Pharmacol, 65, 226, 10.1097/FJC.0000000000000208 Donoghue, 2000, A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9, Circ Res, 87, E1, 10.1161/01.RES.87.5.e1 Harmer, 2002, Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme, FEBS Lett, 532, 107, 10.1016/S0014-5793(02)03640-2 Tipnis, 2000, A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase, J Biol Chem, 275, 33238, 10.1074/jbc.M002615200 Zou, 2020, Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection, Front Med, 14, 185, 10.1007/s11684-020-0754-0 Rice, 2004, Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism, Biochem J, 383, 45, 10.1042/BJ20040634 Thomas, 2010, Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse, Circ Res, 107, 888, 10.1161/CIRCRESAHA.110.219279 Tikellis, 2008, ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes, Diabetes, 57, 1018, 10.2337/db07-1212 Tikellis, 2012, Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease, Int J Pept, 2012, 256294, 10.1155/2012/256294 Turner, 2004, ACE2: from vasopeptidase to SARS virus receptor, Trends Pharmacol Sci, 25, 291, 10.1016/j.tips.2004.04.001 Oudit, 2007, Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice, Cardiovasc Res, 75, 29, 10.1016/j.cardiores.2007.04.007 Lambert, 2005, Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2), J Biol Chem, 280, 30113, 10.1074/jbc.M505111200 Xu, 2017, Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension, Circ Res, 121, 43, 10.1161/CIRCRESAHA.116.310509 Li, 2003, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature, 426, 450, 10.1038/nature02145 He, 2006, Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS, J Pathol, 210, 288, 10.1002/path.2067 Kreutz, 2020, Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19, Cardiovasc Res, 116, 1688, 10.1093/cvr/cvaa097 Furuhashi, 2015, Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker, Am J Hypertens, 28, 15, 10.1093/ajh/hpu086 Mourad, 2020, Interaction between RAAS inhibitors and ACE2 in the context of COVID-19, Nat Rev Cardiol, 17, 313, 10.1038/s41569-020-0368-x Ishiyama, 2004, Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors, Hypertension, 43, 970, 10.1161/01.HYP.0000124667.34652.1a Zhong, 2011, Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression, Regul Pept, 166, 90, 10.1016/j.regpep.2010.09.005 Esler, 2020, Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?, J Hypertens, 38, 781, 10.1097/HJH.0000000000002450 Deshotels, 2014, Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism, Hypertension, 64, 1368, 10.1161/HYPERTENSIONAHA.114.03743 Ferrario, 2005, Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors, Kidney Int, 68, 2189, 10.1111/j.1523-1755.2005.00675.x Vuille-dit-Bille, 2015, Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors, Amino Acids, 47, 693, 10.1007/s00726-014-1889-6 Wang, 2009, Discrepancy between intrarenal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy, Am J Nephrol, 29, 524, 10.1159/000185629 Gu, 2007, Pathology and pathogenesis of severe acute respiratory syndrome, Am J Pathol, 170, 1136, 10.2353/ajpath.2007.061088 Guo, 2020, Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19), JAMA Cardiol, 5, 811, 10.1001/jamacardio.2020.1017 Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395, 507 Wang, 2020, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 323, 1061, 10.1001/jama.2020.1585 Wu, 2020, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med, 180, 934, 10.1001/jamainternmed.2020.0994 Haga, 2008, Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry, Proc Natl Acad Sci U S A, 105, 7809, 10.1073/pnas.0711241105 Liu, 2020, Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Sci China Life Sci, 63, 364, 10.1007/s11427-020-1643-8 Kuster, 2020, SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?, Eur Heart J, 41, 1801, 10.1093/eurheartj/ehaa235 Oudit, 2009, SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS, Eur J Clin Invest, 39, 618, 10.1111/j.1365-2362.2009.02153.x Kassiri, 2009, Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction, Circ Heart Fail, 2, 446, 10.1161/CIRCHEARTFAILURE.108.840124 Bhagat, 2019, Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization, JACC Heart Fail, 7, 1, 10.1016/j.jchf.2018.06.011 Gilstrap, 2017, Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction, J Am Heart Assoc, 6, e004675, 10.1161/JAHA.116.004675 Halliday, 2019, Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial, Lancet, 393, 61, 10.1016/S0140-6736(18)32484-X Pflugfelder, 1993, Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators, J Am Coll Cardiol, 22, 1557, 10.1016/0735-1097(93)90578-O Kane, 2017, Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction, Cardiology, 137, 121, 10.1159/000457946 van den Heuvel, 1997, Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators, J Am Coll Cardiol, 30, 400, 10.1016/S0735-1097(97)00183-6 Nicholls, 1982, Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies, Am J Cardiol, 49, 1497, 10.1016/0002-9149(82)90367-8 Weber, 1999, Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension, Am J Hypertens, 12, 189S, 10.1016/S0895-7061(99)00105-3 1987, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N Engl J Med, 316, 1429, 10.1056/NEJM198706043162301 1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 1992, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, N Engl J Med, 327, 685, 10.1056/NEJM199209033271003 Packer, 1999, Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group, Circulation, 100, 2312, 10.1161/01.CIR.100.23.2312 Cohn, 1991, A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure, N Engl J Med, 325, 303, 10.1056/NEJM199108013250502 Granger, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial, Lancet, 362, 772, 10.1016/S0140-6736(03)14284-5 McMurray, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial, Lancet, 362, 767, 10.1016/S0140-6736(03)14283-3 Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713 Cleland, 2006, The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur Heart J, 27, 2338, 10.1093/eurheartj/ehl250 Massie, 2008, Irbesartan in patients with heart failure and preserved ejection fraction, N Engl J Med, 359, 2456, 10.1056/NEJMoa0805450 Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7 2003, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study, Lancet, 362, 782, 10.1016/S0140-6736(03)14286-9 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301 Braunwald, 2004, Angiotensin-converting-enzyme inhibition in stable coronary artery disease, N Engl J Med, 351, 2058, 10.1056/NEJMoa042739 Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction, Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med, 327, 669 1995, Lancet, 345, 669, 10.1016/S0140-6736(95)90865-X Swedberg, 1992, Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II), N Engl J Med, 327, 678, 10.1056/NEJM199209033271002 1993, Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure, Lancet, 342, 821 Kober, 1995, A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group, N Engl J Med, 333, 1670, 10.1056/NEJM199512213332503 2006, Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study, Arch Intern Med, 166, 659, 10.1001/archinte.166.6.659 Pfeffer, 2003, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, N Engl J Med, 349, 1893, 10.1056/NEJMoa032292 Hansson, 1999, Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial, Lancet, 353, 611, 10.1016/S0140-6736(98)05012-0 Hansson, 1999, Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study, Lancet, 354, 1751, 10.1016/S0140-6736(99)10327-1 2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, 2981, 10.1001/jama.288.23.2981 Lindholm, 2002, Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 1004, 10.1016/S0140-6736(02)08090-X Niskanen, 2001, Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project, Diabetes Care, 24, 2091, 10.2337/diacare.24.12.2091 2000, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, Lancet, 355, 253, 10.1016/S0140-6736(99)12323-7 Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303 Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 Halperin, 2016, Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation, 133, 1426, 10.1161/CIR.0000000000000312 Amat-Santos, 2020, Ramipril in High-Risk Patients With COVID-19, J Am Coll Cardiol, 76, 268, 10.1016/j.jacc.2020.05.040 Chen, 2020, Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication, Diabetes Care, 43, 1399, 10.2337/dc20-0660 Felice, 2020, Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives, Am J Hypertens, 10.1093/ajh/hpaa096 Gao, 2020, Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study, Eur Heart J, 41, 2058, 10.1093/eurheartj/ehaa433 Huang, 2020, The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension, Ann Transl Med, 8, 430, 10.21037/atm.2020.03.229 Iaccarino, 2020, Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension, Hypertension, 76, 366, 10.1161/HYPERTENSIONAHA.120.15324 Inciardi, 2020, Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy, Eur Heart J, 41, 1821, 10.1093/eurheartj/ehaa388 Jung, 2020, Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study, Clin Infect Dis Richardson, 2020, Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA, 323, 2052, 10.1001/jama.2020.6775 Selcuk, 2020, Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?, Clin Exp Hypertens, 42, 738, 10.1080/10641963.2020.1783549 Tedeschi, 2020, Clinical Impact of Renin-angiotensin System Inhibitors on In-hospital Mortality of Patients With Hypertension Hospitalized for Coronavirus Disease 2019, Clin Infect Dis, 71, 899, 10.1093/cid/ciaa492 Xu, 2020, Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis, Front Med, 10.1007/s11684-020-0800-y